文献检索

查找使用阿拉丁产品的科研文献

检索与阿拉丁产品相关的同行评审论文、DOI、PubMed 编号、期刊、作者、CAS 号及研究领域。

科研影响力快照

与阿拉丁产品相关的已发表科研成果

在搜索之前,这些指标可帮助访客快速了解产品关联科研的规模与质量。

346,364+ SCI 论文 与阿拉丁产品引用相关
2,295,288.15 总影响因子 匹配文献记录中影响因子的总和
81.20 最高期刊影响因子 匹配期刊中的最高 IF
6.63 平均期刊影响因子 匹配文献的平均 IF

参考指标 指标基于阿拉丁文献引用数据库及期刊影响因子记录。文献关联仅供科研参考,请以原始文献为准。

热门产品

视图 列表 网格

2 项

设置提升方向
泛凋亡
Discover Oncology · 2024 ·Vol. 15 ·期 1 ·1-13 · IF 2.8

lncRNA FLJ20021 regulates CDK1-mediated PANoptosis in a ZBP1-dependent manner to increase the sensitivity of laryngeal cancer-resistant cells to cisplatin

Yin Xiaoyan,Zhang Haizhong,Wang Jingmiao,Bian Yanrui,Jia Qiaojing,Yang Zhichao,Shan Chunguang

In this study, we investigated the role of the newly discovered lncRNA FLJ20021 in laryngeal cancer (LC) and its resistance to cisplatin treatment. We initially observed elevated lncRNA FLJ20021 levels in cisplatin-resistant LC cells (Hep-2/R). To explore its function, we transfected lncRNA FLJ20021 and cyclin-dependent kinase 1 (CDK1) into Hep-2/R cells, assessing their impact on cisplatin sensitivity and PANoptosis. Silencing lncRNA FLJ20021 effectively reduced cisplatin resistance and induced PANoptosis in Hep-2/R cells. Mechanistically, lncRNA FLJ20021 primarily localized in the nucleus and interacted with CDK1 mRNA, thereby enhancing its transcriptional stability. CDK1, in turn, promoted panapoptosis in a ZBP1-dependent manner, which helped overcome cisplatin resistance in Hep-2/R cells. This study suggests that targeting lncRNA FLJ20021 can be a promising approach to combat cisplatin resistance in laryngeal cancer by regulating CDK1 and promoting PANoptosis via the ZBP1 pathway. These findings open up possibilities for lncRNA-based therapies in the context of laryngeal cancer.

CAS / MDL: 14913-33-8
研究领域: 肿瘤学 · 分子生物学 · 癌症治疗
✓ 已验证 产品关联 DOI PubMed 高影响因子
查看原文 查看 PubMed
Aggregate · 2024 · IF 13.9

Fluorescent Nanoparticles Achieve Efficient Photothermal Conversion and Enhanced Antitumor Efficacy Through Intermolecular Aggregation-Caused Quenching

Jundong Lin,Xiaoxia Cai,Fen Zou,Wenjie Xie,Zhihao Zou,Muqi Chen,Yixun Zhang,Huichan He,Qianfeng Xu,Guowei Zhong,Shanghua Cai,Zhenjie Wu,Jianming Lu,Jianheng Ye,Yingke Liang,Yaqiang Huang,Yangjia Zhuo,Huikang Yang,Weide Zhong

The efficacy of photothermal therapy (PTT) in antitumor applications is often limited by inadequate tumor targeting and low photothermal conversion efficiency (PCE) of photosensitizers. In this study, we designed a photothermal nanoparticle, MPF@IR780, to enhance photosensitizers' targeting and PCE. First, MPF@IR780 improves the delivery of photosensitizers to tumor tissue through the enhanced permeability and retention (EPR) effect. Furthermore, hydrophobic ferrocene was incorporated into the nanoparticle core to increase structural compactness, leading to a strong aggregation-caused quenching (ACQ) effect and an improved PCE of the photosensitizer under near-infrared (NIR) irradiation. Mechanistically, MPF@IR780 induces PANoptosis and ferroptosis in cancer cells through thermal damage and oxidative stress, providing an efficient approach for oncotherapy. This strategy of amplifying the effects of PTT by enhancing the ACQ of photosensitizers offers a promising method for advancing the next generation of PTT.

研究领域: 纳米技术 · 癌症治疗 · 材料科学 · 生物医学工程
✓ 已验证 产品关联 DOI 高影响因子
查看原文 查看 PubMed
已复制

文献关联基于可获得的产品、CAS、DOI 及引用记录。收录不代表作者或出版方对阿拉丁产品的背书,请以原始文献为准。